Fulgent Genetics, Inc. (FLGT) Financial Statements
Fulgent Genetics, Inc. (FLGT) reported trailing twelve-month revenue of $323.9M (up 6.8% year on year) and net income of -$84.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$103.8M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FLGTFulgent Genetics, Inc.Follow FLGT — free
—
Price chart with a free account
- Market cap
- 553.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.02 | 0.02 | 0.02 | 0.03 | 0.42 | 0.99 | 0.62 | 0.29 | 0.28 | 0.32 | 0.32 | |
| Gross profit | 0.01 | 0.01 | 0.01 | 0.02 | 0.33 | 0.78 | 0.37 | 0.10 | 0.11 | 0.13 | 0.12 | |
| Research & development | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 | 0.05 | 0.06 | |
| Operating income | 0.00 | -0.00 | -0.01 | -0.00 | 0.29 | 0.68 | 0.18 | -0.20 | -0.07 | -0.09 | -0.12 | |
| Pre-tax income | -0.00 | -0.00 | -0.00 | 0.00 | 0.29 | 0.68 | 0.18 | -0.17 | -0.05 | -0.07 | -0.09 | |
| Income tax | 0.00 | -0.00 | 0.00 | 0.00 | 0.07 | 0.17 | 0.04 | 0.00 | -0.01 | -0.01 | -0.01 | |
| Net income | -0.01 | -0.00 | -0.01 | -0.00 | 0.21 | 0.51 | 0.14 | -0.17 | -0.04 | -0.06 | -0.08 | |
| Diluted EPS ($) | — | — | -0.31 | -0.02 | 8.91 | 16.38 | 4.63 | -5.63 | -1.41 | -1.97 | -2.83 | |
| Diluted shares (bn) | — | — | 0.018 | 0.019 | 0.024 | 0.031 | 0.031 | 0.030 | 0.030 | 0.031 | — |
USD billions · SEC XBRL
Fulgent Genetics, Inc. — questions
- What is Fulgent Genetics, Inc.'s revenue?
- $323.9M over the twelve months to 2026-06-30, up 6.8% year on year, from its 10-Q and 10-K filings.
- What is Fulgent Genetics, Inc.'s net income?
- -$84.4M over the twelve months to 2026-06-30.
- What is Fulgent Genetics, Inc.'s free cash flow?
- -$103.8M over the twelve months to 2026-06-30.
- What are Fulgent Genetics, Inc.'s diluted earnings per share?
- $-2.83 over the twelve months to 2026-06-30.
Every figure on this page comes from Fulgent Genetics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.